Routine versus selective protamine administration after transcatheter aortic valve implantation
Pending TAVI protamine trial leaves optimal strategy unresolved; results may standardize routine versus selective use if benefit confirmed.
Key result
Routine versus selective protamine administration after transcatheter aortic valve implantation has pending results from a late-breaking trial at the ESC Congress 2026.
Expert reaction lands here the moment POPular ACE TAVI reports.
POPular ACE TAVI is a 1,000-patient, multicenter, randomized, double-blind, placebo-controlled trial comparing routine versus selective protamine administration after transfemoral TAVI, with a primary endpoint of 30-day all-cause death or clinically relevant bleeding. Results will be presented at ESC 2026 Hot Line 7 by Christiaan Overduin. The trial builds on the earlier ACE-PROTAVI study, which showed routine protamine improved hemostasis and reduced minor vascular complications, and expert commentary suggests positive results could definitively establish protamine use as standard practice post-TAVI.
Absolute Event Rate: 0% vs 0%
Christiaan Overduin (Thu,) reported a other. Routine versus selective protamine administration after transcatheter aortic valve implantation has pending results from a late-breaking trial at the ESC Congress 2026.